VIDEO: Curative treatment still a goal for multiple myeloma

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

So I think, as I mentioned earlier, we've made a lot of progress, lots of drugs available. People are living longer, living better with multiple myeloma. But I think for the vast majority of people who are diagnosed, we still don't have a curative treatment for multiple myeloma, so that, to me, is an unmet need. And then, there are probably about 25% of patients who we consider as high risk based on genetic or cytogenetic factors. Those patients still end up having less than optimal responses. These newer treatments don't work as well. So to me, I think focusing on the high-risk myeloma patients and trying to get the same benefits that we do for other patients would be a critical unmet need. The second is, I think as we use more of these treatments, there are side effects that come with it, long-term toxicities. So, focusing on those as our treatment efficacy improves, I think we should be equally focusing on reducing toxicities, burdens of treatment, et cetera, would be the other unmet need, to my mind.